MET激酶结构域激活点突变代表可用MET抑制剂靶向的肺癌及其他恶性肿瘤的独特分子亚群
基于超过60万例患者的综合基因组分析,在多种癌症中发现MET酪氨酸激酶结构域激活点突变作为推定致癌驱动因素,频率约0.5%。临床前模型证实其致癌潜力并显示对I型和II型MET抑制剂敏感性差异。两例携带MET TKD突变(H1094Y、F1200I)的转移性肺腺癌患者对I型MET抑制剂达到确认的部分缓解。
要点
- MET TKD激活点突变在多种癌症中频率约0.5%,常见于H1094、L1195、F1200、D1228、Y1230、M1250等位点。
- 临床前模型证实这些突变的致癌潜力,并显示对I型和II型MET抑制剂的敏感性差异。
- 两例携带H1094Y或F1200I突变的转移性肺腺癌患者对I型MET抑制剂达到确认的部分缓解。
核心结论
- MET TKD激活点突变发生于多种恶性肿瘤,可能赋予对现有MET抑制剂的临床敏感性。
研究设计与样本
- 对超过60万例患者进行综合基因组分析,鉴定MET TKD激活点突变。
- 对 identified 突变进行临床前建模以验证致癌潜力并评估对I型和II型MET抑制剂的敏感性。
- 报告两例携带MET TKD突变(H1094Y、F1200I)且无其他已知致癌驱动因素的转移性肺腺癌患者接受I型MET抑制剂治疗的结果。
主要发现
- 在超过60万例患者中,MET TKD激活点突变作为推定致癌驱动因素见于多种癌症,频率约0.5%。
- 根据OncoKB定义为致癌或可能致癌的最常见MET TKD突变导致H1094、L1195、F1200、D1228、Y1230、M1250等位点的氨基酸替换。
- 临床前建模证实这些改变的致癌潜力,并显示对I型和II型MET抑制剂的敏感性差异模式。
- 两例携带MET TKD突变(H1094Y、F1200I)且无其他已知致癌驱动因素的转移性肺腺癌患者对I型MET抑制剂达到确认的部分缓解。
关键数值与推荐
- MET TKD激活点突变在超过60万例患者中的频率约为0.5%。
- 根据OncoKB定义为致癌或可能致癌的最常见MET TKD突变涉及H1094、L1195、F1200、D1228、Y1230、M1250等位点的氨基酸替换。
- 两例携带H1094Y或F1200I突变的转移性肺腺癌患者对I型MET抑制剂达到确认的部分缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activating point mutations in the MET tyrosine kinase domain (TKD) are oncogenic in a subset of papillary renal cell carcinomas. Here, using comprehensive genomic profiling among >600,000 patients, we identify activating MET TKD point mutations as putative oncogenic driver across diverse cancers, with a frequency of ∼0.5%. The most common mutations in the MET TKD defined as oncogenic or likely oncogenic according to OncoKB resulted in amino acid substitutions at positions H1094, L1195, F1200, D1228, Y1230, M1250, and others. Preclinical modeling of these alterations confirmed their oncogenic potential and also demonstrated differential patterns of sensitivity to type I and type II MET inhibitors. Two patients with metastatic lung adenocarcinoma harboring MET TKD mutations (H1094Y, F1200I) and no other known oncogenic drivers achieved confirmed partial responses to a type I MET inhibitor. Activating MET TKD mutations occur in multiple malignancies and may confer clinical sensitivity to currently available MET inhibitors. Significance: The identification of targetable genomic subsets of cancer has revolutionized precision oncology and offers patients treatments with more selective and effective agents. Here, we demonstrate that activating, oncogenic MET tyrosine kinase domain mutations are found across a diversity of cancer types and are responsive to MET tyrosine kinase inhibitors.
引用
- Pecci F, Nakazawa S, Ricciuti B, et al. Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors. Cancer Discov. 2024. PMID: 38564707. doi:10.1158/2159-8290.CD-23-1217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。